Mult Scler August 2010 PMID 20534644

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.

Naser Sharafaddinzadeh, Ali Moghtaderi, Davood Kashipazha, Nastaran Majdinasab, Bita Shalbafan

Download social card

Mentions

Peak: 2 in Feb 2023

across 3 sources since Feb 2023

Extended reach

207,657

potential audience

Total likes

8,289

Video views

190,400

Mentions per month

Feb 2023 – Oct 2024

Where it's discussed

X / Twitter2 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

The posts reflect a mild interest and agreement with the study, as seen in phrases like 'thread of my spasticity research' and 'stockpiling it lol' which suggest personal engagement and curiosity but lack substantial critique or advocacy for change based on the findings.

AgreementModerate agreement

The posts seem to align with the study's cautious tone, acknowledging its findings without overt disagreement.

InterestModerate interest

The discussion shows some curiosity about the topic, but it remains relatively limited in scope, focusing mainly on personal research instances.

EngagementNeutral engagement

The posts reference personal research efforts but do not delve deeply into analyzing the study itself, indicating moderate engagement.

ImpactNeutral impact

The discussion does not appear to have a broad or transformative influence on opinions or practices regarding MS treatments.

Abstract in brief

This study investigated whether low-dose naltrexone (LDN) can improve quality of life for patients with multiple sclerosis (MS), specifically types called relapsing-remitting and secondary progressive MS.
The 17-week clinical trial found that LDN was generally safe but did not show significant improvements in most quality of life measures compared to a placebo, although some differences in health perception were noted.
The researchers suggest that longer-term studies are needed to determine if LDN could be genuinely effective for improving symptoms or quality of life in MS patients.

Read the full abstract

All mentions

Low-Dose Naltrexone: A Promising Repurposed Drug for Various Diseases

Low-dose naltrexone has the potential to be used in diseases such as multiple sclerosis, COPD, fibromyalgia, and Crohn's disease. This video explores the concept of drug repurposing, emphasizing how existing medications…

Dr. John Campbell · Feb 9, 2023 169,532 views

Low Dose Naltrexone for Long COVID and Chronic Pain Management

Exploring the potential of low-dose naltrexone to treat long COVID symptoms, chronic pain, and inflammation. Currently used off-label, its safety profile is good, but more rigorous studies are needed to confirm…

What's Up Doctor? Dr Michael Cohen · Feb 8, 2023 20,868 views

Richard

@PGC1a_RB · X

RT @mindofintra: thread of my spasticity research (just stockpiling it lol) https://t.co/rc8mJnB099 https://t.co/IgO8LV3Hhl https://t.co/s…

Feb 12, 2024 · 1 share · 15,401 followers View post →

⌬

@MindOfIntra · X

Feb 12, 2024 · 5 likes · 1 share · 1,833 followers View post →

The Use of Low Doses of Naltrexone (LDN) As A Novel Anti ...

News

doi: 10.1177/1352458510366857.PubMed] [CrossRef] [Google Scholar]. I'm sorry, but I can't access external content, including articles on those URLs. However ...

Jan 8, 2026 View →

What is low dose naltrexone (LDN)?